Anti-D Immunoglobulin Market Set To Grow From $2.76 Billion In 2026 To $3.55 Billion By 2030 At A CAGR Of 6.5%
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Anti-D Immunoglobulin Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The anti-D immunoglobulin market has experienced robust growth over the past few years, with projections indicating an increase from $2.59 billion in 2025 to $2.76 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. This expansion during the historical period has been driven by several key factors, including the limited availability of plasma donors, the dependence on manual methods for antibody extraction, a heightened understanding of hemolytic disease, growing utilization in hospitals and clinical settings, and the widespread adoption of intramuscular administration techniques.
The anti-D immunoglobulin market is projected to experience robust growth over the coming years, with expectations of reaching $3.55 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several key factors, including the development of intravenous formulations, the advancement of automated plasma fractionation technologies, an uptick in antenatal screening initiatives, the strengthening of global blood bank infrastructure, and the growth of personalized immunoglobulin therapies. Notable trends shaping this phase include a heightened demand for anti-D immunoglobulin in the management of hemolytic disease, a greater adoption of pre-filled syringes and single-use vials, the expansion of both antenatal and postnatal prophylaxis programs, a rise in distribution channels through hospitals and blood banks, and an amplified focus on safety, purity, and regulatory adherence.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-D Immunoglobulin Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated increase in birth rates is expected to drive future growth in the anti-D immunoglobulin market. Birth rates, defined as the number of live births recorded per 1,000 individuals in a population each year, are rising due to limited access to education and family planning services, which leads to higher fertility rates and larger families. This immunoglobulin assists in managing birth rates by preventing Rh incompatibility during pregnancy, thereby lowering the likelihood of hemolytic disease in newborns and promoting improved outcomes in subsequent pregnancies. As an example, the Centers for Disease Control and Prevention, a US government agency, reported in April 2025 that there were 3,622,673 births in 2024, marking a 1% rise from 2023. Consequently, elevated birth rates are fueling the expansion of the anti-D immunoglobulin market.
Anti-D Immunoglobulin Market Driver: Expansion Of Healthcare Infrastructure Fueling The Growth Of The Market Due To Improved Access To Maternal Care Services
Future growth in the anti-D immunoglobulin market is anticipated to be driven by the ongoing expansion of healthcare infrastructure. This term encompasses the network of facilities, equipment, personnel, and support systems required to deliver medical services to a population. The expansion is being spurred by a growing global population, which increases the demand for medical care and necessitates more hospitals, clinics, and related resources. Enhanced healthcare infrastructure improves access to maternal care, facilitating better screening and the timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, the Department of Health and Social Care, a UK government department, declared plans to allocate over $27 billion (£20 billion) for constructing new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are scheduled to begin or finish by the end of 2023. Thus, the broadening healthcare infrastructure is propelling the anti-D immunoglobulin market forward.
Anti-D Immunoglobulin Market Driver: Expansion Of Prenatal And Antenatal Screening Programs Fueling The Growth Of The Market Due To Improved Maternal-Fetal Risk Management
The growth of the anti-D immunoglobulin market is expected to be propelled by the expansion of prenatal and antenatal screening programs moving forward. These screening programs involve testing pregnant women for blood group compatibility and fetal RhD genotype to prevent hemolytic disease in the fetus and newborn. Their expansion is being driven by the adoption of noninvasive prenatal testing (NIPT) using cell-free fetal DNA, which enables precise determination of fetal RhD status. Such programs support the effective use of anti-D immunoglobulin by identifying Rh-negative mothers early in pregnancy, monitoring for potential sensitization events, and ensuring timely intervention to prevent Rh incompatibility, thereby safeguarding both maternal and fetal health. As a case in point, the World Health Organization (WHO), a Switzerland-based international public health agency, estimated in July 2025 that around 1.2 million pregnant women were living with HIV in 2023, with approximately 84% receiving antiretroviral medicines to prevent mother-to-child transmission. Therefore, the widening of prenatal and antenatal screening initiatives is driving the anti-D immunoglobulin market’s growth.
Anti-D Immunoglobulin Market Segment Performance And Strategic Opportunities
The anti-d immunoglobulin market covered in this report is segmented –
1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications
4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories
Subsegments:
1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials
2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials
Anti-D Immunoglobulin Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.
Access The Complete Anti-D Immunoglobulin Market Report:
Anti-D Immunoglobulin Market Largest Region By Revenue And Market Share
North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
